Clinical Trial Update: Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3. [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial evaluates how Zidovudine (AZT) treatment affects HIV-1 burden in blood and lymphoid tissue in HIV-1-infected patients with CD4 count…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• AZT (Zidovudine) (Zidovudine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED